Overview
Manidipine (INN) is a calcium channel blocker (dihydropyridine type) that is used clinically as an antihypertensive. It is selective for vasculature and does not produce effects on the heart at clinically relevant dosages.
Indication
For the treatment of hypertension.
Associated Conditions
- Mild to Moderate Hypertension
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2017/04/10 | Phase 4 | Terminated | |||
2008/03/04 | Phase 3 | Completed | University of Erlangen-Nürnberg Medical School |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| No FDA approvals found for this drug. | |||||
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| Manidipine Hydrochloride Tablets | 国药准字H20227058 | 化学药品 | 片剂 | 3/1/2023 | |
| Manidipine Hydrochloride Tablets | 国药准字H20120017 | 化学药品 | 片剂 | 5/5/2022 | |
| Manidipine Hydrochloride Tablets | 国药准字H20120016 | 化学药品 | 片剂 | 5/5/2022 | |
| Manidipine Hydrochloride Tablets | 国药准字H20133274 | 化学药品 | 片剂 | 3/1/2023 |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.